MSD’s Lipfendra takes on injectable rivals for cholesterol-lowering market supremacy

Summary

MSD's Lipfendra is positioned as an oral alternative to injectable cholesterol-lowering therapies with a lower price point. The article highlights its potential advantages for patients but lacks specific clinical data or approval information.